Diltiazem reduces the contractility of extraocular muscles in vitro and in vivo.
Diltiazem, a Ca-channel blocker that is used clinically for the treatment of hypertension and cardiac arrhythmias, reduces the contractility of extraocular muscles. Exposure of rabbit extraocular muscle to diltiazem in vitro reduces the sustained tension that is generated by the tonic, multiply innervated fibers, and decreases the baseline, or resting, tension of the muscle. When diltiazem is injected into a selected extraocular muscle in the rabbit in vivo, it causes a temporary weakening of the muscle, which is indicated by a deviation of eye position. These in vivo effects are of short duration, are easily reproducible, and vary with dosage. The results of this study raise the possibility that diltiazem may be used as an alternative to the surgical treatment of strabismus and other oculomotor dysfunctions including blepharospasm.
Jacoby
J
J
Daniel B. Kirby Eye Institute, Department of Ophthalmology, New York University Medical Center, NY 10016.
Kahn
D N
DN
Pavlica
M R
MR
Ko
K
K
Breinin
G M
GM
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D004110:Diltiazem / Q000494:pharmacology*; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects*; D009801:Oculomotor Muscles / Q000187:drug effects* / Q000201:enzymology / Q000294:innervation; D011817:Rabbits; D014743:Videotape Recording
D000251:Adenosine Triphosphatases; D004110:Diltiazem